HCG share price has declined by 30% in the past three months and 38% since our downgrade in February, 2018 and the recent correction offers another opportunity to take a positive view on the stock.
HCG’s performance was decent with recovery promising. Its Q1FY21 revenues and ebitda declined 28% and 57% YoY, respectively. Lower costs led to ebitda exceeding our estimates by 29%. Recovery trends ...
Hi. I am looking for HCG for injection (Pregnyl, Novarel, Profasi etc) & am finding it impossible to find. Even more impossible to find is bacteriostatic water for injection (not sterile water because ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback